{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=20", "query": { "condition": "Multiple Cancers", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 4774, "total_pages": 478, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T17:47:46.521Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07863765", "title": "Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Differentiated Thyroid Gland Carcinoma", "Metastatic NUT Carcinoma", "Metastatic Thyroid Gland Anaplastic Carcinoma", "Metastatic Thyroid Gland Medullary Carcinoma", "Refractory Differentiated Thyroid Gland Carcinoma", "Stage III Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage III Thyroid Gland Medullary Carcinoma AJCC v8", "Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage IV Thyroid Gland Medullary Carcinoma AJCC v8", "Unresectable Differentiated Thyroid Gland Carcinoma", "Unresectable NUT Carcinoma", "Unresectable Thyroid Gland Anaplastic Carcinoma", "Unresectable Thyroid Gland Medullary Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Enfortumab Vedotin", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2027-05-05", "completion_date": "2031-05-05", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-25T17:47:46.521Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07863765" }, { "nct_id": "NCT07589634", "title": "A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ramantamig", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2026-06-30", "completion_date": "2030-11-08", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-25T17:47:46.521Z", "location_count": 5, "location_summary": "Goodyear, Arizona • Beverly Hills, California • Irvine, California + 2 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07589634" }, { "nct_id": "NCT02527434", "title": "Study of Tremelimumab in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Bladder Cancer", "Triple-negative Breast Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Tremelimumab monotherapy", "type": "BIOLOGICAL" }, { "name": "MEDI4736 monotherapy", "type": "BIOLOGICAL" }, { "name": "MEDI4736 + tremelimumab combination therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "150 Years", "sex": "ALL", "summary": "18 Years to 150 Years" }, "enrollment_count": 64, "start_date": "2015-11-02", "completion_date": "2023-03-28", "has_results": true, "last_update_posted_date": "2023-11-15", "last_synced_at": "2026-10-25T17:47:46.521Z", "location_count": 3, "location_summary": "San Francisco, California • Memphis, Tennessee • Houston, Texas", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02527434" }, { "nct_id": "NCT03333486", "title": "Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Leukemia in Remission", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Acute Myeloid Leukemia With FLT3/ITD Mutation", "Acute Myeloid Leukemia With Gene Mutations", "Aplastic Anemia", "B-Cell Non-Hodgkin Lymphoma", "CD40 Ligand Deficiency", "Chronic Granulomatous Disease", "Chronic Leukemia in Remission", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Congenital Amegakaryocytic Thrombocytopenia", "Congenital Neutropenia", "Congenital Pure Red Cell Aplasia", "Glanzmann Thrombasthenia", "Immunodeficiency Syndrome", "Myelodysplastic Syndrome", "Myelofibrosis", "Myeloproliferative Neoplasm", "Paroxysmal Nocturnal Hemoglobinuria", "Plasma Cell Myeloma", "Polycythemia Vera", "Recurrent Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndrome", "Severe Aplastic Anemia", "Shwachman-Diamond Syndrome", "Sickle Cell Disease", "T-Cell Non-Hodgkin Lymphoma", "Thalassemia", "Waldenstrom Macroglobulinemia", "Wiskott-Aldrich Syndrome" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "75 Years", "sex": "ALL", "summary": "1 Year to 75 Years" }, "enrollment_count": 31, "start_date": "2017-12-07", "completion_date": "2023-08-28", "has_results": true, "last_update_posted_date": "2025-07-04", "last_synced_at": "2026-10-25T17:47:46.521Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03333486" }, { "nct_id": "NCT06564038", "title": "A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukaemia", "Small Lymphocytic Lymphoma", "Mantle-cell Lymphoma", "Large B-cell Lymphoma", "B-cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Surovatamig", "type": "DRUG" }, { "name": "Prednisone (or equivalent)", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 408, "start_date": "2025-01-30", "completion_date": "2029-06-11", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-25T17:47:46.521Z", "location_count": 12, "location_summary": "Boston, Massachusetts • Hackensack, New Jersey • New Brunswick, New Jersey + 8 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06564038" }, { "nct_id": "NCT02958969", "title": "Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Venous Thromboembolism", "Multiple Myeloma" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gregory Piazza", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2018-02-28", "completion_date": "2019-11-19", "has_results": true, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-10-25T17:47:46.521Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02958969" }, { "nct_id": "NCT02939183", "title": "Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Multiple Myeloma" ], "interventions": [ { "name": "Immediate Release (IR) Formulation", "type": "DRUG" }, { "name": "Gastro-Retentive (GR) Formulation", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 61, "start_date": "2017-01-17", "completion_date": "2022-10-06", "has_results": true, "last_update_posted_date": "2024-09-26", "last_synced_at": "2026-10-25T17:47:46.521Z", "location_count": 13, "location_summary": "West Hollywood, California • Tampa, Florida • Atlanta, Georgia + 10 more", "locations": [ { "city": "West Hollywood", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02939183" }, { "nct_id": "NCT03445559", "title": "A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Clinical Order Check", "type": "BEHAVIORAL" }, { "name": "Academic Detailing", "type": "BEHAVIORAL" }, { "name": "Audit and Feedback", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 58, "start_date": "2018-04-09", "completion_date": "2027-02-28", "has_results": true, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-25T17:47:46.521Z", "location_count": 11, "location_summary": "Palo Alto, California • West Los Angeles, California • West Haven, Connecticut + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "West Los Angeles", "state": "California" }, { "city": "West Haven", "state": "Connecticut" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03445559" }, { "nct_id": "NCT06055803", "title": "Heart Health After Cancer Treatment (HEART-ACT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Intake Session", "type": "BEHAVIORAL" }, { "name": "Individual Sessions", "type": "BEHAVIORAL" }, { "name": "Group Sessions", "type": "BEHAVIORAL" }, { "name": "Graduation", "type": "BEHAVIORAL" }, { "name": "Exercise", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-11-07", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-10-25T17:47:46.521Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06055803" }, { "nct_id": "NCT03713320", "title": "SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous T-Cell Lymphoma/Mycosis Fungoides" ], "interventions": [ { "name": "Cobomarsen", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "miRagen Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2019-04-02", "completion_date": "2020-12-01", "has_results": true, "last_update_posted_date": "2022-04-08", "last_synced_at": "2026-10-25T17:47:46.521Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03713320" } ] }